Answers are grounded in this paper and cite their sources.
Background: Platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) vary in composition and are associated with heterogeneous clinical outcomes. We examined donor, procedural, and disease-related factors associated with product composition and clinical prognosis. Methods: Six databases and registers were searched. Eighteen human studies were included. Two independent reviewers assessed risk of bias using Quality in Prognosis Studies (QUIPS), and certainty was rated using a Grading of Recommendations Assessment, Development and Evaluation (GRADE)-informed approach. Because of heterogeneity, findings were synthesized narratively. Results: Thirteen studies concerned PRP (seven composition, six clinical) and five concerned BMAC (three composition, two clinical). Baseline whole-blood platelet count was positively associated with final PRP platelet concentration in two studies (low-certainty evidence), without establishing greater administered platelet dose or clinical benefit. BMAC cellular yield varied with harvesting conditions and cellular assay definitions; demographic associations were inconsistent. Associations between radiographic osteoarthritis severity and outcomes after PRP were heterogeneous and of very-low certainty. Conclusions: Donor biology and processing characteristics are associated with selected orthobiologic product measures, but corresponding clinical implications remain uncertain. Single-arm prognostic studies cannot establish treatment-effect modification or composition-mediated benefit. Registration: PROSPERO CRD420261483107. Level of Evidence: Level III; systematic review of predominantly observational and prognostic-factor studies.
No takes yet. Share an insight, caveat, or question.
PEZONE et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: